title: Treating the Host Response to Ebola Virus Disease with Generic Statins and Angiotensin Receptor Blockers.
abstract: Treatments targeting the Ebola virus may eventually be shown to work, but they will not have an impact on overall Ebola mortality in West Africa. Endothelial dysfunction is responsible for the fluid and electrolyte imbalances seen in Ebola patients. Because inexpensive generic statins and angiotensin receptor blockers restore endothelial barrier integrity, they can be used to treat the host response in these patients. In Sierra Leone, approximately 100 Ebola patients were treated with this combination, and reports indicate that survival was greatly improved.
authors.affiliation: Retired Physician, Sergy Haut, France dfedson@wanadoo.fr.
authors.forename: David S
authors.initials: DS
authors.lastname: Fedson
authors.affiliation: University of Illinois College of Medicine, Chicago, Illinois, USA.
authors.forename: Jeffrey R
authors.initials: JR
authors.lastname: Jacobson
authors.affiliation: Practicing Physician, Trondheim, Norway.
authors.forename: Ole Martin
authors.initials: OM
authors.lastname: Rordam
authors.affiliation: Alpert Medical School, Brown University, Providence, Rhode Island, USA.
authors.forename: Steven M
authors.initials: SM
authors.lastname: Opal
mesh_terms: D000354:Africa, Western; D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use*; D042783:Endothelial Cells / Q000187:drug effects* / Q000502:physiology*; D019142:Hemorrhagic Fever, Ebola / Q000188:drug therapy*; D006801:Humans; D006903:Hydroxymethylglutaryl CoA Reductases / Q000627:therapeutic use*; D012807:Sierra Leone; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D057911:Angiotensin Receptor Antagonists; D006903:Hydroxymethylglutaryl CoA Reductases